Clinical Development. Subject to the terms of this Agreement, the Designated Party will lead all preclinical and clinical development pursuant to the applicable Development and Commercialization Plan, and the other Party’s scientific personnel will participate as appropriate. The Designated Party will keep the JSC fully informed of all activities conducted by the Designated Party with respect to any Collaboration Product.
Appears in 2 contracts
Sources: Collaboration Agreement (Seattle Genetics Inc /Wa), Collaboration Agreement (Seattle Genetics Inc /Wa)